Madrigal Pharmaceuticals (MDGL) Short Interest Ratio & Short Volume $302.17 -0.34 (-0.11%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$300.90 -1.28 (-0.42%) As of 08/1/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Madrigal Pharmaceuticals Short Interest DataMadrigal Pharmaceuticals (MDGL) has a short interest of 3.79 million shares. This marks a -4.53% decrease in short interest from the previous month. The short interest ratio (days to cover) is 11.2, indicating that it would take 11.2 days of the average trading volume of 359,418 shares to cover all short positions.Current Short Interest3,790,000 sharesPrevious Short Interest3,970,000 sharesChange Vs. Previous Month-4.53%Dollar Volume Sold Short$1.18 billionShort Interest Ratio11.2 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares22,200,000 sharesPercentage of Shares Shorted17.07%Today's Trading Volume236,785 sharesAverage Trading Volume359,418 sharesToday's Volume Vs. Average66% Short Selling Madrigal Pharmaceuticals? Sign up to receive the latest short interest report for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartMDGL Short Interest Over TimeMDGL Days to Cover Over TimeMDGL Percentage of Float Shorted Over Time Madrigal Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/20253,790,000 shares $1.18 billion -4.5%N/A11.2 $311.14 6/30/20253,970,000 shares $1.20 billion -4.3%22.8%11.9 $302.64 6/15/20254,150,000 shares $1.23 billion +6.7%23.8%12.6 $295.57 5/31/20253,890,000 shares $1.08 billion -2.8%23.1%11.6 $276.70 5/15/20254,000,000 shares $1.17 billion -2.4%23.8%10.7 $291.82 4/30/20254,100,000 shares $1.37 billion +1.7%N/A11 $333.91 4/15/20254,030,000 shares $1.29 billion +0.8%23.9%10.7 $321.10 3/31/20254,000,000 shares $1.32 billion -2.2%23.8%9.9 $331.23 3/15/20254,090,000 shares $1.42 billion +9.1%24.3%10.1 $348.35 2/28/20253,750,000 shares $1.28 billion -1.3%22.3%9.3 $341.27 Get the Latest News and Ratings for MDGL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/15/20253,800,000 shares $1.28 billion -4.5%22.6%9.8 $337.20 1/31/20253,980,000 shares $1.33 billion -2.5%N/A9.9 $334.80 1/15/20254,080,000 shares $1.12 billion -0.7%N/A8.6 $274.41 12/31/20244,110,000 shares $1.27 billion -13.1%N/A9.8 $308.57 12/15/20244,730,000 shares $1.44 billion +10.5%N/A11.2 $304.50 11/30/20244,280,000 shares $1.40 billion -3.4%N/A10.6 $328.19 11/15/20244,430,000 shares $1.28 billion -2.2%N/A11.3 $288.58 10/31/20244,530,000 shares $1.17 billion +11.9%N/A13.1 $259.34 10/15/20244,050,000 shares $875.49 million +4.9%N/A15.1 $216.17 9/30/20243,860,000 shares $819.17 million +3.5%N/A13.8 $212.22 9/15/20243,730,000 shares $901.91 million -0.8%N/A13.5 $241.80 8/31/20243,760,000 shares $929.21 million +0.3%N/A11.5 $247.13 8/15/20243,750,000 shares $916.88 million +1.9%N/A9.5 $244.50 7/31/20243,680,000 shares $1.05 billion -10.5%N/A8.6 $284.66 7/15/20244,110,000 shares $1.15 billion +0.7%N/A9.1 $279.95 6/30/20244,080,000 shares $1.14 billion -7.9%N/A9.1 $280.16 6/15/20244,430,000 shares $1.23 billion -15.3%N/A9.5 $277.59 5/31/20245,230,000 shares $1.24 billion +25.4%N/A9.4 $236.16 5/15/20244,170,000 shares $882.91 million +4.8%N/A8.1 $211.73 4/30/20243,980,000 shares $812.00 million +16.7%N/A6.9 $204.02 4/15/20243,410,000 shares $788.97 million +1.5%N/A5.9 $231.37 3/31/20243,360,000 shares $897.25 million +3.1%N/A6 $267.04 3/15/20243,260,000 shares $881.41 million -5.8%20.2%5.9 $270.37 2/29/20243,460,000 shares $817.25 million +2.1%21.4%7.3 $236.20 2/15/20243,390,000 shares $753.33 million +8.0%21.1%7.6 $222.22 1/31/20243,140,000 shares $680.47 million -5.1%19.5%7.2 $216.71 1/15/20243,310,000 shares $780.50 million +1.9%21.1%8.6 $235.80 12/31/20233,250,000 shares $751.99 million +5.9%20.7%7.9 $231.38 12/15/20233,070,000 shares $727.99 million -11.5%19.5%6.7 $237.13 11/30/20233,470,000 shares $705.45 million +0.3%24.4%7.1 $203.30Jeff Bezos Launches "ChatGPT Killer"? (Ad)Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% of his time focused on AI… but Nova is only part of the story. Behind the scenes, Amazon has been quietly investing in a breakthrough called “Helios” tech—a core enabler of the $40 trillion AI revolution. While Nova grabs headlines, this technology could be what truly transforms Amazon’s future. But one tiny startup—not Amazon—may offer the bigger upside.Get the name of the small company at the center of the $40 trillion AI boom. 11/15/20233,460,000 shares $559.41 million +1.5%24.3%7.7 $161.68 10/31/20233,410,000 shares $448.01 million +13.3%24.7%8.2 $131.38 10/15/20233,010,000 shares $422.51 million +13.6%21.8%7.6 $140.37 9/30/20232,650,000 shares $387.01 million +24.4%19.2%7.4 $146.04 9/15/20232,130,000 shares $374.65 million +8.7%16.5%6.3 $175.89 8/31/20231,960,000 shares $352.80 million +8.3%15.2%6.3 $180.00 8/15/20231,810,000 shares $315.25 million -1.1%14.0%5.7 $174.17 7/31/20231,830,000 shares $375.70 million -3.2%13.8%5.3 $205.30 7/15/20231,890,000 shares $426.71 million +7.4%14.3%5.4 $225.77 6/30/20231,760,000 shares $406.56 million +10.0%13.3%4.7 $231.00 6/15/20231,600,000 shares $408.85 million +10.3%12.1%4.7 $255.53 5/31/20231,450,000 shares $403.69 million +15.1%10.4%3.9 $278.41 5/15/20231,260,000 shares $365.77 million -8.7%9.0%3.1 $290.29 4/30/20231,380,000 shares $430.56 million -6.8%10.0%3.3 $312.00 4/15/20231,480,000 shares $354.89 million +19.4%10.8%3.7 $239.79 3/31/20231,240,000 shares $300.40 million +3.3%9.2%3.1 $242.26 3/15/20231,200,000 shares $286.57 million +16.5%8.7%2.3 $238.81 2/28/20231,030,000 shares $279.14 million +9.2%7.4%1.6 $271.01 2/15/2023942,900 shares $266.14 million 0.0%7.2%1.5 $282.26 1/31/2023943,300 shares $271.91 million -3.3%7.2%1.6 $288.25 1/15/2023975,300 shares $292.57 million -12.9%7.5%1.6 $299.98 12/30/20221,120,000 shares $325.08 million -52.7%9.0%1.9 $290.25 12/15/20222,370,000 shares $149.07 million +9.7%19.1%4.3 $62.90 11/30/20222,160,000 shares $151.44 million +3.9%17.4%7.3 $70.11 11/15/20222,080,000 shares $146.68 million +14.3%16.8%7.9 $70.52 10/31/20221,820,000 shares $128.89 million +17.4%14.7%7.4 $70.82 10/15/20221,550,000 shares $100.27 million +1.3%12.5%6.6 $64.69 9/30/20221,530,000 shares $99.43 million +2.7%12.4%7.2 $64.99 9/15/20221,490,000 shares $103.70 million +1.4%12.1%7.4 $69.60 8/31/20221,470,000 shares $106.02 million -4.6%11.9%7.8 $72.12 8/15/20221,540,000 shares $118.13 million -3.8%12.5%8.6 $76.71 7/31/20221,600,000 shares $100.51 million +3.2%12.9%8.4 $62.82 7/15/20221,550,000 shares $107.24 million -4.3%12.5%8.1 $69.19 6/30/20221,620,000 shares $115.96 million -2.4%13.1%8.1 $71.58 6/15/20221,660,000 shares $112.71 million +3.8%13.4%8.6 $67.90 5/31/20221,600,000 shares $106.22 million -5.3%12.9%8.5 $66.39 5/15/20221,690,000 shares $111.08 million -2.9%13.6%8.8 $65.73 4/30/20221,740,000 shares $121.80 million +1.8%14.0%8.2 $70.00 4/15/20221,710,000 shares $135.89 million -5.5%13.8%7.3 $79.47 3/31/20221,810,000 shares $177.60 million -9.1%14.6%7.8 $98.12 3/15/20221,990,000 shares $179.10 million +0.5%16.0%8.5 $90.00 2/28/20221,980,000 shares $183.84 million -1.5%16.0%8.1 $92.85 2/15/20222,010,000 shares $180.72 million +12.3%16.2%8.4 $89.91 1/31/20221,790,000 shares $103.07 million +19.3%14.4%8.5 $57.58 1/15/20221,500,000 shares $117.68 million +8.7%12.1%9.4 $78.45 12/31/20211,380,000 shares $116.94 million -6.8%11.1%9.6 $84.74 12/15/20211,480,000 shares $110.82 million +7.3%11.9%10.8 $74.88 11/30/20211,380,000 shares $114.14 million +2.2%12.0%12 $82.71 11/15/20211,350,000 shares $122.00 million -3.6%11.8%12.7 $90.37 10/29/20211,400,000 shares $108.85 million +3.7%12.2%13.3 $77.75Jeff Bezos Launches "ChatGPT Killer"? (Ad)Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% of his time focused on AI… but Nova is only part of the story. Behind the scenes, Amazon has been quietly investing in a breakthrough called “Helios” tech—a core enabler of the $40 trillion AI revolution. While Nova grabs headlines, this technology could be what truly transforms Amazon’s future. But one tiny startup—not Amazon—may offer the bigger upside.Get the name of the small company at the center of the $40 trillion AI boom. 10/15/20211,350,000 shares $116.33 million -6.9%12.1%13.5 $86.17 9/30/20211,450,000 shares $115.70 million No Change13.0%14.1 $79.79 9/15/20211,450,000 shares $115.10 million -7.1%13.0%11.9 $79.38 8/31/20211,560,000 shares $129.09 million -5.5%14.0%12.2 $82.75 8/13/20211,650,000 shares $140.02 million +3.1%14.8%10.9 $84.86 7/30/20211,600,000 shares $139.71 million -4.2%14.4%10.4 $87.32 7/15/20211,670,000 shares $157.95 million No Change15.0%11 $94.58 6/30/20211,670,000 shares $162.67 million -5.1%15.0%10.9 $97.41 6/15/20211,760,000 shares $185.66 million -7.9%15.8%12.4 $105.49 5/28/20211,910,000 shares $214.49 million -7.3%17.2%14.1 $112.30 5/14/20212,060,000 shares $271.12 million +1.0%18.9%16.5 $131.61 4/30/20212,040,000 shares $280.68 million -8.5%18.7%14.8 $137.59 4/15/20212,230,000 shares $269.70 million -5.1%21.8%12.3 $120.94 3/31/20212,350,000 shares $273.80 million -4.5%23.4%12.7 $116.51 3/15/20212,460,000 shares $289.89 million -7.5%24.5%12.4 $117.84 2/26/20212,660,000 shares $327.34 million -4.0%26.5%13.5 $123.06 2/12/20212,770,000 shares $334.67 million +5.3%28.6%14.4 $120.82 1/29/20212,630,000 shares $304.11 million -8.4%26.0%13.7 $115.63 1/15/20212,870,000 shares $327.18 million +4.7%28.4%17.9 $114.00 12/31/20202,740,000 shares $304.47 million +12.3%27.1%19.3 $111.12 12/15/20202,440,000 shares $294.58 million -2.4%24.2%17.2 $120.73 11/30/20202,500,000 shares $297.78 million +5.5%24.8%16.9 $119.11 11/15/20202,370,000 shares $303.57 million -4.4%23.5%16.3 $128.09 10/30/20202,480,000 shares $318.23 million +0.8%24.6%18.5 $128.32 10/15/20202,460,000 shares $312.94 million No Change24.4%19.1 $127.21 9/30/20202,460,000 shares $292.08 million -13.7%24.4%19.4 $118.73 9/15/20202,850,000 shares $304.72 million +2.5%28.3%21.4 $106.92 8/31/20202,780,000 shares $299.41 million -1.8%27.6%25 $107.70 8/14/20202,830,000 shares $301.37 million +0.4%32.6%24.3 $106.49 MDGL Short Interest - Frequently Asked Questions What is Madrigal Pharmaceuticals' current short interest? Short interest is the volume of Madrigal Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of July 15th, traders have sold 3,790,000 shares of MDGL short. Learn More on Madrigal Pharmaceuticals' current short interest. What is a good short interest ratio for Madrigal Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MDGL shares currently have a short interest ratio of 11.0. Learn More on Madrigal Pharmaceuticals's short interest ratio. Which institutional investors are shorting Madrigal Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Madrigal Pharmaceuticals: Twin Tree Management LP, Jane Street Group LLC, 683 Capital Management LLC, Cubist Systematic Strategies LLC, Caption Management LLC, Twin Tree Management LP, Susquehanna International Group LLP, HAP Trading LLC, Jane Street Group LLC, Walleye Trading LLC, Walleye Capital LLC, and Citigroup Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Madrigal Pharmaceuticals' short interest increasing or decreasing? Madrigal Pharmaceuticals saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 3,790,000 shares, a decrease of 4.5% from the previous total of 3,970,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Madrigal Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "biotechnology" compare to Madrigal Pharmaceuticals: Biogen Inc. (2.67%), United Therapeutics Corporation (3.64%), Incyte Corporation (3.73%), Neurocrine Biosciences, Inc. (3.26%), Exelixis, Inc. (6.92%), BioMarin Pharmaceutical Inc. (3.19%), Exact Sciences Corporation (3.96%), Halozyme Therapeutics, Inc. (7.88%), Ionis Pharmaceuticals, Inc. (8.30%), Repligen Corporation (6.40%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Madrigal Pharmaceuticals stock? Short selling MDGL is an investing strategy that aims to generate trading profit from Madrigal Pharmaceuticals as its price is falling. MDGL shares are trading down $0.34 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Madrigal Pharmaceuticals? A short squeeze for Madrigal Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MDGL, which in turn drives the price of the stock up even further. How often is Madrigal Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MDGL, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies BIIB Short Interest UTHR Short Interest INCY Short Interest NBIX Short Interest EXEL Short Interest BMRN Short Interest EXAS Short Interest HALO Short Interest IONS Short Interest RGEN Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MDGL) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
